Figure 2.

Proportion of patients with ≥30%, ≥50%, and ≥75% reduction in number of monthly migraine days at month 3 (day-61 to day-90) compared to baseline. Eighty-nine of 91 patients completed the 3-month treatment period and provided data for the efficacy analysis. Numbers depicts proportion of patients, who achieved the corresponding reduction in monthly migraine days; light: ≥30%, medium: ≥50%, and dark: ≥75%.